Active Biotech
Active Biotech AB is a biotechnology company focused on developing first-in-class immunomodulatory treatments for oncology and immunology indications. The company is headquartered in Lund, Sweden, and is listed on NASDAQ Stockholm. Active Biotech's core projects include tasquinimod for hematological malignancies, laquinimod for inflammatory eye disorders, and naptumomab for solid tumors. Their strategy involves advancing these projects to clinical proof-of-concept and securing partnerships for further development and commercialization.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueIncludes tasquinimod and naptumomab for cancer treatment
Includes laquinimod for inflammatory eye disorders
Clinical development and research services for drug development
Customers
Active Biotech primarily serves pharmaceutical companies and research institutions seeking innovative treatments for cancer and inflammatory diseases. Their customers are typically partners who collaborate on clinical trials and commercialization efforts. The company targets organizations looking for novel immunomodulatory therapies with high unmet medical needs. Active Biotech's partnerships are crucial for advancing their drug candidates through clinical phases and into the market.
Collaborate on drug development and commercialization
Engage in clinical trials and research collaborations
Partner for clinical development and market entry
Strategy
Active Biotech's strategic priorities include advancing their clinical pipeline, securing partnerships for drug development, and achieving regulatory milestones. The company focuses on developing tasquinimod, laquinimod, and naptumomab to clinical proof-of-concept stages. Establishing collaborations with pharmaceutical companies and research institutions is crucial for commercialization. Active Biotech aims to expand their market presence by targeting high unmet medical needs in oncology and immunology.
To reach proof-of-concept and attract partnerships
For development and commercialization support
To enable market entry and commercialization
Geography
Active Biotech is based in Lund, Sweden, and operates primarily in Europe and the United States. The company conducts clinical trials across these regions, leveraging collaborations with academic institutions and research partners. Their geographic presence is strategic for accessing key markets and research expertise. The company's partnerships with European and US institutions are vital for advancing their clinical programs and achieving regulatory approvals.
Risks
Active Biotech faces significant risks related to pharmaceutical development, including clinical trial outcomes, regulatory approvals, and commercialization challenges. The company's financial stability depends on securing partnerships and funding for ongoing projects. Industry-specific risks include competition from other biotech firms and technological advancements. Additionally, macroeconomic uncertainties and geopolitical factors may impact financial markets and investment availability.
- Clinical Trial OutcomesImpact: CriticalLikelihood: High
Uncertain results can delay or halt development
- Partnership DependenceImpact: HighLikelihood: High
Essential for funding and commercialization
- Regulatory ApprovalsImpact: High
Necessary for market entry
- CompetitionImpact: MediumLikelihood: Medium
Other firms may develop superior treatments
Accounting
Judgemental itemsDepends on partnership milestones
Impact: Significant for financial results
Affects quarterly financial performance
Impact: High variability in costs
Similar listed companies
Publicly listed companies with a comparable business focus.
BioInvent International
BINV · Health Care
BioInvent International is a biotechnology company focused on developing novel immuno-modulatory antibodies for cancer therapy.
BioNTech SE
BNTX · Biological Products, (No Diagnostic Substances)
BioNTech SE is a biotechnology company focused on discovering and developing immunotherapies and other medicines, with a major commercial base in COVID-19 vaccines and a growing oncology pipeline.
Purple Biotech Ltd
PPBT · Pharmaceutical Preparations
IMMUTEP Ltd
IMMP · Pharmaceutical Preparations
Immutep Ltd is a clinical-stage biotechnology company developing immunotherapies for cancer and autoimmune diseases.
CytomX Therapeutics, Inc.
CTMX · Pharmaceutical Preparations
CytomX Therapeutics is a clinical-stage biopharmaceutical company built around its PROBODY platform, which masks biologic drug activity until it reaches the tumor microenvironment.
Evaxion A/S
EVAX · Biological Products, (No Diagnostic Substances)
Evaxion A/S is a clinical-stage biotech company focused on developing vaccines and other drug candidates using its AI-Immunology™ platform.
Last updated: 24/09/2026